ACHE and Alzheimer disease: While both AChE inhibitors and NMDA receptor antagonists demonstrate symptomatic efficacy in AD management, it is crucial to note that these pharmacotherapies provide only palliative benefits, neither halting disease progression nor addressing underlying neuropathology [135].